Bristol-Myers Squibb (BMY) Has Fallen To An 8-Month Low On Study Results
Bristol-Myers Squibb (BMY) announced Monday morning that its Phase 3 study, of Opdivo 3 mg/kg plus low-dose Yervoy in first-line advanced non-small cell lung cancer patients reduced the risk of death by 42% versus chemotherapy alone.
Source: RTTNews